ONO-4538 Multicenter, Open-label, Uncontrolled, Phase I Multiple Dose Study in Solid Tumor

Trial Profile

ONO-4538 Multicenter, Open-label, Uncontrolled, Phase I Multiple Dose Study in Solid Tumor

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 23 Jan 2015

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Ono Pharmaceutical
  • Most Recent Events

    • 18 Jan 2015 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 14 Oct 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top